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Background: The eNOS 894G/T polymorphism (GG, GT, and TT) is associated with cardiovascular mortality and may
influence cardiovascular diseases as a genetic risk factor. Moreover, this polymorphism has an impact on
intraoperative hemodynamics during cardiac surgery with cardiopulmonary bypass (CPB). In this study, we analyzed
the influence of this gene polymorphism on early clinical outcome in patients who underwent cardiac surgery with
CPB. Also, we performed a 5-year follow-up, assessing the impact of this polymorphism on long-term mortality.
Method: 500 patients who underwent cardiac surgery with CPB between 2006 and 2007 were included in this
prospective single centre study. Genotyping for the eNOS gene polymorphism was performed by polymerase chain
reaction amplification.
Results: Genotype distribution of 894G/T was: GG 50.2%; GT 42.2%; TT 7.8%. Cardiovascular risk factors were equally
distributed between the different genotypes of the eNOS 894G/T polymorphism. No significant difference among the
groups was shown regarding Euroscore, SAPS II and APACHE II. Perioperative characteristics were also not affected by
the genotypes, except for the consumption of norepinephrine (p = 0.03) and amiodarone (p = 0.01) which was higher
in the GT allele carrier. The early postoperative course was quite uniform across the genotypes, except for mean
intensive care unit length of stay which was significantly prolonged in GT carriers (p = 0.001). The five-year follow-up
was 100% complete and showed no significant differences regarding mortality between the groups.
Conclusion: Our results show that the eNOS 894G /T polymorphism is not associated with early and late clinical
outcome after cardiac surgery. Thus, this polymorphism can actually not help to identify high risk groups in the
heterogeneous population of individuals who undergo cardiac surgery with CPB.Background
Nitric oxide (NO) is an endothelium-derived relaxing
factor (EDRF) which represents one of the most relevant
molecules involved in biological systems. NO is synthe-
sized by NO Synthase (NOS) from L-arginine. There are
three types of NOS: inducible NOS (iNOS), neural NOS
(nNOS), and endothelial NOS (eNOS) [1]. The human
eNOS gene is located on the chromosome No. 7 (7q35-36)
which consists of 26 exons with an entire length of 21 kb* Correspondence: Popov@med.uni-goettingen.de
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reproduction in any medium, provided the orand is constitutively expressed in vascular endothelial cells.
eNOS is the key enzyme responsible for basal vascular pro-
duction of NO [2]. In addition to influencing relaxation of
vascular smooth muscle cells, endothelium-derived NO in-
hibits platelets [3] and leukocytes [4] adhesion to vascular
endothelium, inhibits vascular smooth cell migration and
proliferation [5], and limits the oxidation of atherogenic
low-density lipoprotein [6].
Furthermore, it has been shown that the production of
NO is significantly increased during and after cardiopul-
monary bypass (CPB) [7]. The systemic endotoxemia
that occurs with the establishment of CPB is a potent
stimulus for the release of proinflammatory cytokinesd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lease [8]. The increased release of NO due to expression
of iNOS may not only contribute to the reduced activity
of eNOS, but may also lead to increased vascular perme-
ability and other manifestations of systemic inflamma-
tion after CPB [9,10]. Therefore, changes in eNOS
activity and NO bioavailability after cardiac surgery with
CPB may lead to vasomotor abnormalities with im-
paired regulation of myocardial perfusion, altered per-
ipheral vascular resistance, and vascular permeability
with endorgan edema.
Several polymorphisms in the gene encoding eNOS
influence the production and functional activity of the
enzyme. A substitution of guanine to thymine at nucleo-
tide 894 in exon 7 of the eNOS gene (894G- > T) which
leads to an amino acid change from Glu to Asp at codon
298 (also called Glu298Asp) was shown to reduce basal
NO production [11]. Functional consequences suggest
that 894 T SNP are associated with an up to 80% de-
creased eNOS activity and an increased susceptibility to
cleavage of the eNOS protein of the T-genotypes, both
resulting in decreased NO generation [12,13]. Some
studies have shown that T-allele carriers have an in-
creased risk of hypertension [14], coronary spasm [15],
myocardial infarction [16], and coronary artery disease
[17]. A recent clinical study indicates that patients who
are homozygous for the T-allele, have an enhanced
responsiveness to α1- adrenergic stimulation during car-
diac surgery with CPB [18]. Based on these pathophysio-
logical backgrounds, we conducted a prospective study to
determine the influence of the eNOS G894T on early and
late outcome after cardiac surgery with CPB. Early mor-
bidity and long-term mortality after cardiac surgery with
CPB were our key points of interest in this study.Methods
Participants
After approval by the local ethics committee (University
of Göttingen, Germany), data of 500 adult Caucasian
patients who underwent cardiac surgery with CPB
were analysed. Patients with known neoplasms were
excluded from this observation. A written informed
consent was obtained from each participant included
in this prospective study. A part of the present pa-
tient population was used for several genetic investi-
gations [19-21].
Genomic DNA was extracted from patient’s EDTA
blood samples collected before surgery. After extractingTable 1 Endothelial 894 G/T NO-Synthase genotypes and alle
894G/T GG GT TT
n = 500 251 (50.2%) 210 (42%) 39 (7.8%the DNA, genotyping was performed and patients were
divided in three groups according to their genotype (GG,
GT, and TT) (Table 1).
Definitions
The preoperative patient characteristics included age, gen-
der, BMI (body mass index), smoking habits, hypertension,
history of diabetes, renal disorder, hypercholesterolemia,
positive family history of cardiovascular disorders, left ven-
tricular ejection fraction, peripheral vascular disease, his-
tory of neurocerebral events, pulmonary hypertension,
and chronic obstructive pulmonary disease. Additionally,
preoperative medications, urgency of surgery, concomitant
procedures, as well as additive Euroscore, Acute Physi-
ology and Chronic Health Evaluation Score (APACHE II),
and Simplified Acute Physiology Score (SAPS II) were re-
corded (Table 2).
Perioperative patient characteristics, such as intraopera-
tive cross-clamp and cardiopulmonary bypass time, oxygen-
ation index (PaO2/FiO2), positive end-expiratory pressure
(PEEP), partial pressure of carbon dioxide (PCO2), arterial
pH, compliance, presence of infiltrates and lung injury
score were prospectively evaluated intra- and over 24 hours
postoperatively. Hemodynamic measurements comprised
heart rate (HR), mean arterial pressure (MAP), central ven-
ous pressure (CVP), and mean pulmonary artery pressure
(PAP), pulmonary capillary wedge pressure (PCWP). Car-
diac index (CI), systemic vascular resistance (SVRI) and
pulmonary vascular resistance (PVRI) indices were calcu-
lated using routine formulas. Extended hemodynamic mea-
surements were done in cases of poor condition and
inotropic dependency. Additionally, catecholamine support,
administration of amiodarone, cortisone, nitroglycerin, and
vasopressin were recorded. All perioperative variables are
summarized in Table 3.
Postoperative details included transfusion and clotting
factor requirement, intraaortic ballon pump (IABP)
usage, need for extracorporeal membrane oxygenation
(ECMO) support, length of hospital and intensive care
unit (ICU) stay, and in-hospital mortality (Table 4).
Non-elective operation was defined as the necessity of
surgery within the same week of referral (urgent case) or
the necessity to take the patient to theatre out of normal
working hours and before the next morning’s operating
list (emergency cases). In-hospital mortality was defined
as intraoperative death or mortality during the same
hospitalization. A five-year follow-up for all initially sur-
vived patients was performed with the view to assessing
the long-term mortality.lic frequencies of patients
G-allele T-allele HWE p-value
) 712 (71%) 288 (29%) 0.86
Table 2 Baseline characteristics
Variable
GG GT TT p
value(n = 251) (n = 210) (n = 39)
Age (years) 68 ± 10 67 ± 11 68 ± 9 0.97
Male/female 163/88 134/76 26/13 0.93
Risk factors
Body mass index (kg/m2) 28 ± 4.6 27. ± 4.8 27 ± 4.5 0.18
Smoking 85 66 16 0.49
Hypertension 184 144 34 0.05
Hypercholesterolemia 125 95 21 0.48
Diabetes mellitus 78 63 13 0.91
Positive family history 40 31 8 0.66
Ejection fraction (%) 53 ± 14 52 ± 15 62 ± 10 0.07
Renal disorder 29 33 6 0.41
Peripheral disease 17 12 6 0.09
Neurocerebral events 36 26 4 0.70
Pulmonary hypertension 26 11 3 0.13
COPD 18 18 4 0.74
Dialysis 1 2 0 0.66
Preoperative medications
ß-blockers 158 129 29 0.31
ACE inhibitors 135 103 25 0.19
Oral nitrates 55 33 5 0.15
Antiarrhythmics 11 7 1 0.77
Diuretics 106 80 13 0.46
Antilipid agents 119 94 25 0.08
Antidiabetics 51 35 8 0.58
Antihypertensive agents 54 49 8 0.87
Bronchodilators 6 8 1 0.66
Anticoagulation 163 145 29 0.40
Urgency of surgery
Elective (n = 396) 202 161 33 0.41
Urgent (n = 41) 26 13 2 0.21
Emergency (n = 63) 23 36 4 0.03
Associated surgical procedures
CABG (n = 251) 118 111 22 0.26
Valve (n = 107) 58 44 5 0.32
Combined procedures (n = 101) 55 36 10 0.36
Other procedures (n = 41) 20 19 2 0.78
Euroscore additive 5 ± 4 6 ± 4 5 ± 3 0.19
COPD: chronic obstructive pulmonary disease, ACE: angiotensin-converting
enzyme, CABG: Coronary artery bypass grafting.
Table 3 Perioperative data
Variable
GG GT TT p value
(n = 251) (n = 210) (n = 31)
Pulmonary function
PaO2/FiO2 262 ± 108 259 ± 95 244 ± 9 0.80
PEEP (mbar) 7 ± 2 7 ± 2 8 ± 3 0.50
PCO2 (mmHg) 40 ± 5 40 ± 4 40 ± 4 0.67
pH arterial 7.39 ± 0.05 7.39 ± 0.05 7.39 ± 0.05 0.50
Compliance (ml/mbar) 47 ± 21 45 ± 18 50 ± 31 0.59
Infiltrates (Quadrants) 1.24 ± 1 1.34 ± 1 1.31 ± 1 0.46
Lung injury score 1.28 ± 1 1.34 ± 1 1.33 ± 1 0.55
Scores
APACHE II Score 14 ± 6 16 ± 7 16 ± 6 0.06
SAPS II Score 25 ± 7 25 ± 8 25 ± 6 0.51
Hemodynamic
Heart rate (bpm) 81 ± 12 82 ± 14 85 ± 15 0.46
MAP (mmHg) 80 ± 8 80 ± 9 82 ± 8 0.25
CVP (mmHg) 11 ± 4 11 ± 3 11 ± 3 0.76
PCWP(mmHg) 16 ± 4 14 ± 5 15 ± 2 0.07
PAP (mmHg) 25 ± 5 26 ± 9 24 ± 9 0.83
CI (l/min/m2) 3.2 ± 3.2 2.8 ± 0.8 2.7 ± 0.4 0.99
SVRI (dyn∙s-1∙m2∙cm-5) 958 ± 394 987 ± 403 861 ± 213 0.83
PVRI (dyn∙s-1∙m2∙cm-5) 202 ± 177 219 ± 155 189 ± 81 0.36
Inotropes
Epinephrine (mg/d) 9.6 ± 129 3.4 ± 15 0.5 ± 1.4 0.24
Norepinephrine (mg/d) 1.4 ± 6.0 4.6 ± 19.3 0.2 ± 0.66 0.03
Enoximone (mg/d) 17 ± 107 29 ± 200 0.2 ± 1.28 0.57
Dobutamine (mg/d) 10 ± 50 11 ± 63 21 ± 58 0.29
Other agents
NTG (mg/d) 10 ± 25 12 ± 32 13 ± 20 0.24
Amiodarone (mg/d) 28 ± 159 105 ± 361 62 ± 10 0.01
Cortisone (mg/d) 44 ± 367 37 ± 227 9 ± 58 0.12
Vasopressin (iU/d) 0.16 ± 2.5 0.19 ± 1.89 0 0.40
Operative characteristics
Cross-clamp time (min) 93 ± 37 93 ± 39 105 ± 42 0.27
Cardiopulmonary bypass
time (min)
143 ± 75 141 ± 58 162 ± 69 0.15
PEEP: positive end-expiratory pressure, APACHE II Score: Acute Physiology and
Chronic Health Evaluation Score, SAPS II Score: Simplified Acute Physiology
Score, HR: Heart rate, MAP: mean arterial pressure, CVP: central venous
pressure, PCWP: pulmonary capillary wedge pressure, PAP: mean pulmonary
artery pressure, CI: cardiac index, SVRI: systemic vascular resistance, PVRI:
pulmonary vascular resistance, NTG: nitroglycerin.
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Genomic DNA was extracted from peripheral blood
leukocytes using a commercially available kit and was per-
formed using polymerase chain reaction amplificationaccording to previously described protocols [22]. Patients
were divided into the following three groups according to
their genotypes: GG, GT, and TT. The clinical data were
blinded to the laboratory personal who performed genetic
analysis.
Table 4 Postoperative course
Variable
GG GT TT p
value(n = 251) (n = 210) (n = 39)
Red blood cells transfused
(ml/d)
215 ± 554 298 ± 684 267 ± 398 0.05
Fresh Frozen Plasma (ml/d) 64 ± 387 97 ± 702 33 ± 127 0.66
Prothrombin complex
concentrates (iU/d)
6 ± 94 17 ± 184 0 0.66
IABP 15 21 1 0.13
ECMO 0 1 0 0.50
Length of ICU stay (d) 6 ± 12 10 ± 17 5 ± 6 0.001
Hospitality stay (d) 25 ± 20 27 ± 22 22 ± 11 0.91
Early Mortality (n = 41)
Overall (8.2%) (%) n = 500 18 20 3 0.65
Elective cases (%) n = 396 11 14 1 0.32
Urgent cases (%) n = 41 2 3 1 0.15
Emergency cases (%) n = 63 5 3 1 0.29
Long-term Mortality
(n = 125)
Overall (25%) (%) n = 500 64 50 11 0.88
Age at surgery (years) 72 ± 8 72 ± 7 73 ± 4 0.67
Survival after surgery (days) 500 ± 493 497 ± 588 599 ± 578 0.71
Age at death (years) 74 ± 8 73 ± 7 75 ± 4 0.64
IABP: intraaortic ballon pump, ECMO: extracorporeal membrane oxygenation,
ICU: intensive care unit.
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Prior to commencement of this study, a power analysis
was done. The calculated appropriate sample size needed
to attain a given power of 80% and to achieve a signifi-
cance of p < 0.05 was 500 patients. All statistical analyses
were computed by the commercially available software
(SPSS for Windows, Version 13.0, SPSS Inc. Chicago,
USA). Continuous variables are presented as the mean ±
SD, and categorical variables are presented as absolute
numbers or percentages. Data were evaluated for normal-
ity before statistical analysis. Groups were compared using
analysis of variance for normally distributed data or by the
nonparametric Kruskal–Wallis test for non-normally dis-
tributed variables. The Scheffe’ post hoc test was used as
appropriate.
Contingency table methods, including the Chi-square
test and the Fisher exact test, were used to analyse cat-
egorical data. Allele frequencies in the study population
were counted and compared to the expected distribution
in normal population by Hardy-Weinberg’s equilibrium
and checked by χ2-test. Statistical difference was consid-
ered at p < 0.05.
The Kaplan–Meier method was used for survival ana-
lysis and the log rank test was performed for the com-
parison among the groups in terms of mortality.Results
Baseline characteristics
The G894T polymorphism of the eNOS gene was deter-
mined, and 3 groups were defined according to the
genotype (GG, GT, and TT). Of the studied subjects 251
patients were homozygous G-allele carrier (GG), 210 pa-
tients were heterozygous for the G894T polymorphism
(GT) and 39 patients were homozygous (TT) for the
transversion in this gene. According to this, we found an
allele frequency of 0.71 for G-allele and 0.29 for T-allele
in studied subjects. Genotype distribution of the eNOS
G894T polymorphism was consistent with the Hardy-
Weinberg equilibrium. The genotype frequencies and al-
lelic of the polymorphism in this study closely matched
those published in previous studies [18,20] and are sum-
marized in Table 1. There were no significant differences
in baseline characteristics (Table 2), except for urgency
of surgery. In the GT group more patients underwent
emergency surgery (p = 0.03).
Perioperative characteristics
No differences were observed in the statistical analysis
with regard to PaO2/FiO2, PCO2, arterial pH, PEEP, lung
injury score, APACHE II score, and SAPS II score.
Hemodynamic measurements performed over 24 hours
postoperatively revealed no significant differences among
the three groups concerning HR, MAP, CVP, PCWP, PAP,
CI, SVRI and PVRI. There was no difference in consump-
tion of epinephrine, enoximone, dobutamine, nitroglycer-
ine (NTG), vasopressin, and cortisone. However, the
consumption of norepinephrine (p = 0.03) and amioda-
rone (p = 0.01) was significantly higher in patients who
were heterozygous for the eNOS 894G/T polymorphism.
Furthermore, no difference was observed with regard
to CPB time and aortic cross clamp time. All results are
summarized in Table 3.
Postoperative course
The postoperative morbidity and in-hospital mortality
are presented in Table 4. There was no relation between
red blood cells transfusion, administration of fresh fro-
zen plasma or prothrombin complex concentrates, and
genotype. IABP and ECMO usage was comparable in all
groups. The mean postoperative hospital length of stay
was also comparable among the genotype carriers. How-
ever, the mean ICU stay showed statistical differences
among the groups. Patients who were heterozygous for
the eNOS G894T polymorphism had a prolonged stay at
the ICU (p = 0.001).
The overall in-hospital mortality rate was 8.2% for all
patients included in this study (41 of 500) and did not
reach statistical significance comparing the three groups
(GG: n = 18; GT: n = 20; TT: n = 3) (p = 0.65). Further-
more, the in-hospital mortality was quite uniform across
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ation among genotypes was observed.
Long-term mortality
Long-term follow-up of initial survivors was available in
all cases (100%) and median follow-up time was 5 years.
During this period, 12 patients died from cardiac related
complications, 10 patients died from multi organ failure,
8 died from cerebrovascular accidents, 5 patients had a
cancer related death, and in the remaining 45 patients
the cause of death was unknown (n = 84). The overall
mortality was 25% (n = 125) and there was no significant
difference in the statistical analysis with regard to geno-
types distribution (GG: n = 66, GT: n = 50, TT: n = 11,
log rank test p = 0.88) (Figure 1).
Discussion
This study examined the association of eNOS G894T
polymorphism with in-hospital mortality and morbidity
after cardiac surgery with CPB. The investigated eNOS
gene polymorphism revealed no different risk for the de-
tected homozygous TT genotype. Furthermore, homozy-
gous TT carriers did not contribute to a higher prevalence
of postoperative in-hospital mortality after cardiac surgery
with CPB. Our genotype frequencies for eNOS G894T
polymorphism were in accordance with previously re-
ported results in other European populations [18,23].
NO plays a crucial role in regulating a wide spectrum
of functions in the cardiovascular system, including va-
sorelaxation, vascular smooth muscle cell migration and
proliferation, as well as platelet aggregation. PreviousFigure 1 Cumulative survival (overall mortality after 5 years was 25%studies provide evidence that defects of endothelial NO
function cause endothelial dysfunction [24,25]. Moreover,
open heart surgery with CBP remains associated with
systemic inflammation and suboptimal outcome in many
individuals. Systemic hypotension, myocardial failure, in-
creased vascular permeability and consequent dysfunction
of endorgans are manifested by inflammatory changes and
changes of eNOS activity [26,27]. The increased release of
inflammatory substances may potentially lead to changes
in vasomotor regulation, endothelial integrity and vascular
permeability that may compromise the recovery of pa-
tients undergoing cardiac surgery with CPB [23].
Several genetic polymorphisms of the eNOS gene have
been reported as “susceptibility genes” in a number of
cardiovascular diseases. It has been shown, that the
eNOS G894T polymorphism is associated with reduced
basal NO [11]. In addition, this polymorphism was asso-
ciated with hypertension [14], coronary spasm [15] in-
creased risk for myocardial infarction [16], and coronary
artery disease [17]. In a previous study, the eNOS G894T
polymorphism was reported to be associated with an en-
hanced vascular responsiveness to phenylephrine and in-
fluenced systemic hemodynamics in patients undergoing
surgery with CPB [18], thus suggesting a difference in
vascular reactivity among genotype carriers. Our results
are partially in accordance with those findings. In the
present study extended systemic hemodynamic analyses
were performed during the perioperative period in cases
of poor condition. An interaction between the eNOS
G894T polymorphism and perioperative hemodynamics
was not observed within the first 24 hours. Otherwise,).
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administration of amiodarone (p = 0.03) reached statis-
tical significance for patients who were heterozygous for
the eNOS 894G/T polymorphism. Although, T allele car-
riers did not show a decrease of SVRI and PVRI after
cardiac surgery with CPB, there might be an influence
on the postoperative hemodynamics. Furthermore, in
our study, we detected no relationship between the T-al-
lele and increased aortic cross-clamp time and CPB
time. Therefore, we can exclude the possibility that this
may have influenced the results of the present study. It
might have been possible, that SVRI and PVRI in T allele
carriers could have achieved statistical difference, if ad-
ministration of catecholamine had been declined. Our
observation may be explainable, because in cases of im-
paired hemodynamics, patients were immediately treated
with drugs to avoid hemodynamic complications. An-
other reason why we failed to show statistical differences
in hemodynamics could be that we did not use a domin-
ant or additive model of inheritance. Philip et al. com-
bined all T-allele carriers (GT + TT) to a single group
(dominant model of inheritance), because the sample size
was less [18]. Liakopoulos et al. did not detect significant
associations between this polymorphism and changes in
hemodynamics after cardiac surgery with CPB [22] and
have also used the dominant model of inheritance. Our
observation is more powerful compared to previous re-
search, as the number of subjects used in our study is lar-
ger than that in two studies previously reported.
Relatively small sample size can be a significant contribu-
tory factor for the failure to detect and replicate associa-
tions across studies. Interestingly, Ruel et al. demonstrated
that altered release of NO after cardiac surgery with CPB
may lead to reduced peripheral and pulmonary resistance,
and abnormal vascular permeability. Furthermore, these
abnormalities may lead to organ dysfunction, such as organ
edema, impaired regulation of myocardial perfusion and
can contribute to myocardial and endothelial dysfunction
[28]. Thus, this observed vasomotor dysfunction might be
induced by the eNOS G894T polymorphism and/or CPB
leading to an increased susceptibility to cleavage of the
eNOS protein of the T genotypes.
The investigations on the influence of the eNOS G894T
polymorphism on early clinical outcome in patients under-
going cardiac surgery with CPB was the primary endpoint
of the present study.
The major finding is that the eNOS G894T poly-
morphism did not show an interaction with the clinical
outcome in patients undergoing cardiac surgery. The op-
erative morbidity and mortality of patients underwent
cardiac surgery with CPB was low. There was no con-
duction disturbance. The overall in-hospital mortality
rates observed in the present study are acceptable and
were comparable to 30-day mortality in cardiac surgery[29]. However, in our study GT allele carriers had a pro-
longed ICU stay (p = 0.001). This finding is not surprising,
because significant more GT allele carriers underwent an
emergency operation (p = 0.03). Urgent and/or emergent
surgery has long been known to be a risk factor for
prolonged ICU stay [30]. Moreover, in the long-term fol-
low-up which was 100% complete, there was no influence
of the eNOS G894T polymorphism on mortality. We ob-
served an overall mortality of 25% after five years which is
acceptable for heterogeneous elderly cardiac surgical pa-
tients including emergency procedures and combined
procedures.
It is important to note that this study has several limi-
tations. Although our patients were distributed accord-
ing to Hardy-Weinberg equilibrium, our study is limited
by the relatively small number of patients in the TT
group, which may have affected the clinical outcome.
Because the study population was selected from patients
undergoing cardiac surgery, the sample size was smaller
than in gene polymorphism studies with non-surgical
patients suffering from cardiovascular disorders [16,17].
Another limitation is a short perioperative observation
period only lasting for 24 hours postoperatively. The in-
fluence of the eNOS G894T polymorphism might have
been higher and the sensitivity and specificity for analysis
of data would have been more appropriate if the recording
time had been longer. However, to our knowledge, this is
the first investigation on the eNOS G894T polymorphism
regarding its clinical impact on early and late mortality in
cardiac surgery patients.Conclusions
In conclusion, the results of the present study demon-
strate that homozygous T-allele carriers do not have a
significantly increased risk for in-hospital or long-term
mortality after cardiac surgery with CPB. Thus, the poly-
morphism can actually not help to identify high risk
groups in the heterogeneous population of individuals
who undergo cardiac surgery with CPB.
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